David is a Chartered UK and European patent attorney and works in the life science group at Greaves Brewster. David has particular experience in antibody and vaccine technology, as well as gene editing technology involving antisense RNA and CRISPR. Prior to joining Greaves Brewster, David was in-house counsel and head of oppositions with Novartis AG.
David enjoys utilising his experience as an in-house attorney to provide a perspective on the client’s experience. He is especially sensitive to the needs of the client and to adapting his way of working to suit a particular client’s requirements. He is always conscious of the client’s goals and resources and he is valued by clients for his creative thinking and responsive approach.
David originally studied virology, but this also gave him a broad background in immunology and microbiology, including medical microbiology. During his studies, David spent a year carrying out molecular biology research at Novartis in Vienna.
As well as UK, European and Worldwide patent prosecution, David advises on SPCs, paediatric extensions, regulatory exclusivity, oppositions & appeals as well as litigation matters. Having managed the portfolios of blockbuster antibodies, David has been involved in due diligences, multi-million dollar licensing negotiations, high profile European opposition matters, litigation before the UK High Court and regulatory matters before the CJEU.